Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -0.47% 420.00 410.00 430.00 422.00 420.00 422.00 15,217 12:39:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 250

Renalytix AI PLC Notice of Results

26/02/2020 7:00am

UK Regulatory (RNS & others)

Renalytix Ai (LSE:RENX)
Historical Stock Chart

From Dec 2019 to May 2020

Click Here for more Renalytix Ai Charts.


RNS Number : 0948E

Renalytix AI PLC

26 February 2020

Renalytix AI plc

("RenalytixAI", the "Company" or the "Group")

Notice of results

Investor briefing

Renalytix AI plc (LSE : RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it will release its interim results for the six months ended 31 December 2019, on Tuesday 3 March 2020.

Investor briefing

A briefing open to all investors will take place on Monday 9 March 2020 at the Brand Exchange, 3 Birchin Lane, London EC3V 9BW from 5.15pm for a 5.30pm start and will be followed by light refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email

For further information, please contact:

Renalytix AI plc                                                           
James McCullough, CEO                                                                   Via Walbrook PR 
Stifel (Nominated Adviser & Joint Broker)                                            Tel: 020 7710 7600 
Alex Price / Jonathan Senior / Ben Maddison 
N+1 Singer (Joint Broker)                                                            Tel: 020 7496 3000 
Aubrey Powell / George Tzimas (Corporate Finance) 
Tom Salvesen / Mia Gardner (Corporate Broking) 
Walbrook PR Limited                                      Tel: 020 7933 8780 or 
Paul McManus / Lianne Cawthorne                                          Mob: 07980 541 893 / 07584 391 

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have chronic kidney disease. It is reported that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

For more information, visit

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

February 26, 2020 02:00 ET (07:00 GMT)

1 Year Renalytix Ai Chart

1 Year Renalytix Ai Chart

1 Month Renalytix Ai Chart

1 Month Renalytix Ai Chart
ADVFN Advertorial
Your Recent History
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200531 08:06:19